Home > Search Results: Péter, Bohuš
Search:
Search Tips :: Advanced Search
Search collections:
Sort by: Display results: Output format:
National Repository of Grey Literature 2 records found  Search took 0.00 seconds. 
Prodysrrhythmogenic effects of drugs
 Péter, Bohuš ; Hrdina, Radomír (advisor) ; Tilšer, Ivan (referee)
The most common cardiac arrhythmia is atrial fibrillation. In most patients it is not the only heart disease. The main goal of therapy is to maintain a normal heart rhythm. This can be achieved by restoring the sinus rhythm or by controlling the ventricle response. The anticoagulation therapy may be needed to reduce the risk of tromboembolism. Several arrhythmias, including atrial fibrillation can be treated by a catheter ablation. This method is highly successful in treatment of supraventricular arrhythmias. The long-therm treatment of ventricular arrhythmias may require implantation of a cardioverter-defibrilator. Serious bradycardias are treated by permanent cardiac stimulation. The efficacy of pharmacologic treatment can be proved only in a clinical trial. Methods of preclinical identification of proarrhythmogenic substances are quite limited. Electrophysiology, drug effects, effects of genetic polymorphism can be studied mostly on models and preparations. Use of antiarrhythmics from groups IA and IB of the Vaughan Williams classification is now limited. Besides the beta blockers used in various indications, the antiarrhythmics from group III are most often used. It is likely that a new drug, dronedarone will be approved for treatment of atrial fibrillation. Positive effect on mortality, and in...
Detailed record
Prodysrrhythmogenic effects of drugs
 Péter, Bohuš ; Hrdina, Radomír (advisor) ; Tilšer, Ivan (referee)
The most common cardiac arrhythmia is atrial fibrillation. In most patients it is not the only heart disease. The main goal of therapy is to maintain a normal heart rhythm. This can be achieved by restoring the sinus rhythm or by controlling the ventricle response. The anticoagulation therapy may be needed to reduce the risk of tromboembolism. Several arrhythmias, including atrial fibrillation can be treated by a catheter ablation. This method is highly successful in treatment of supraventricular arrhythmias. The long-therm treatment of ventricular arrhythmias may require implantation of a cardioverter-defibrilator. Serious bradycardias are treated by permanent cardiac stimulation. The efficacy of pharmacologic treatment can be proved only in a clinical trial. Methods of preclinical identification of proarrhythmogenic substances are quite limited. Electrophysiology, drug effects, effects of genetic polymorphism can be studied mostly on models and preparations. Use of antiarrhythmics from groups IA and IB of the Vaughan Williams classification is now limited. Besides the beta blockers used in various indications, the antiarrhythmics from group III are most often used. It is likely that a new drug, dronedarone will be approved for treatment of atrial fibrillation. Positive effect on mortality, and in...
Detailed record

Interested in being notified about new results for this query?
Subscribe to the RSS feed.
Digital Repository :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.2
Maintained by admin.invenio@techlib.cz
This site is also available in the following languages:
Česky  English